-
公开(公告)号:US20240409621A1
公开(公告)日:2024-12-12
申请号:US18702507
申请日:2022-08-15
Applicant: XIAMEN UNIVERSITY
Inventor: Zizheng ZHENG , Yongpeng SUN , Siyu LEI , Hongsheng QIANG , Li CHEN , Ningshao XIA
IPC: C07K16/10 , A61K39/00 , A61P31/14 , G01N33/569
Abstract: The present invention relates to the field of immunology and molecular virology, and in particular relates to the field of the prevention and treatment of RSV. Specifically, provided are a monoclonal antibody capable of specifically binding to a new epitope between an Ø epitope and a V epitope on a pre-F protein or a new epitope between an II epitope and a V epitope, and the use thereof in the detection, prevention and/or treatment of RSV infection and/or diseases caused by the infections.
-
2.
公开(公告)号:US20240350615A1
公开(公告)日:2024-10-24
申请号:US18292538
申请日:2022-07-21
Inventor: Tong CHENG , Rui ZHU , Hongwei YANG , Longfa XU , Yu LIN , Zhenhong ZHOU , Xiangzhong YE , Ningshao XIA
IPC: A61K39/125 , A61K39/00 , A61K39/385 , A61P31/16 , C07K14/005 , C07K16/10 , G01N33/569 , G01N33/68
CPC classification number: A61K39/125 , A61K39/385 , A61P31/16 , C07K14/005 , C07K16/1009 , G01N33/56983 , G01N33/6854 , A61K2039/6075 , C07K2317/14 , C07K2317/24 , C07K2317/565 , C07K2317/76 , C12N2770/32722 , C12N2770/32723 , G01N2333/095
Abstract: The present invention belongs to the field of immunobiology, and relates to an epitope polypeptide, such as a general affinity epitope polypeptide of human rhinovirus, and the use thereof. The present invention further relates to an antibody capable of binding to the epitope polypeptide and the use thereof. The present invention further relates to the use of the affinity epitope polypeptide or the antibody in the preparation of drugs or in methods for treating and/or preventing and/or diagnosing human rhinovirus and/or identifying a titer of human rhinovirus and/or identifying a titer of a neutralizing antibody of human rhinovirus. The affinity epitope polypeptide and antibody can be used in drugs or methods for treating and/or preventing and/or diagnosing human rhinovirus and/or identifying a titer of human rhinovirus and/or identifying a titer of a neutralizing antibody of human rhinovirus.
-
公开(公告)号:US20230218576A1
公开(公告)日:2023-07-13
申请号:US18001167
申请日:2021-06-01
Applicant: YANG SHENG TANG COMPANY, LTD. , XIAMEN UNIVERSITY
Inventor: Tianying ZHANG , Jiali CAO , Tianshu SHI , Jian MA , Shaojuan WANG , Quan YUAN , Jun ZHANG , Ningshao XIA
IPC: A61K31/415 , A61P31/20
CPC classification number: A61K31/415 , A61P31/20
Abstract: The present application relates to the field of antiviral treatment of hepatitis B, and specifically relates to the use of a compound represented by formula I in treatment against HBV virus.
-
公开(公告)号:US20230057621A1
公开(公告)日:2023-02-23
申请号:US17786937
申请日:2020-10-26
Applicant: XIAMEN UNIVERSITY , YANG SHENG TANG COMPANY, LTD.
Inventor: Yixin CHEN , Guosong WANG , Pengfei HUANG , Ruiqi CHEN , Lina LIN , Qiangyuan HAN , Ningshao XIA
IPC: A61K31/675 , A61P31/22 , A61K38/21 , A61K31/7056 , A61K31/522 , A61K31/192 , A61K31/616 , A61K31/405
Abstract: The present invention relates to the medical field, and in particular to the use of adefovir dipivoxil and a structural analog thereof for treating pseudorabies virus. In particular, the invention relates to the use of a compound as shown in formula (I), a stereoisomer thereof, a solvate thereof, a pharmaceutically acceptable salt thereof or a solvate of the pharmaceutically acceptable salt thereof for inhibiting the pseudorabies virus, treating pseudorabies virus infections or treating diseases related to pseudorabies virus infections.
-
公开(公告)号:US20190316176A1
公开(公告)日:2019-10-17
申请号:US16314356
申请日:2017-06-29
Applicant: Xiamen University
Inventor: Shiyin ZHANG , Shengxiang GE , Jin WANG , Jun ZHANG , Ningshao XIA
Abstract: A ribonucleic acid (RNA) reverse transcription amplification method, comprising the steps of reverse transcription of RNA into cDNA and immediate amplification of cDNA, characterized in that the process of reverse transcription of RNA into cDNA is completed during the process that a cDNA amplification reaction system is heated to reach the reaction condition for cDNA amplification. The RNA reverse transcription amplification method can combine the reaction condition for reverse transcription of RNA into cDNA with the reaction condition for cDNA amplification, thereby significantly shorten the time required for RNA reverse transcription amplification. And in the whole process of RNA reverse transcription amplification, there is no need to change the instrument temperature, and thus, it is possible to achieve detection at any time.
-
公开(公告)号:US20180207257A1
公开(公告)日:2018-07-26
申请号:US15924511
申请日:2018-03-19
Inventor: Jun ZHANG , Jin WANG , Chunyan YANG , Ying GU , Shaowei LI , Ningshao XIA
IPC: A61K39/12 , C12N7/00 , C07K14/005
CPC classification number: A61K39/12 , C07K14/005 , C12N7/00 , C12N2710/20022 , C12N2710/20023 , C12N2710/20034
Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.
-
公开(公告)号:US20250101083A1
公开(公告)日:2025-03-27
申请号:US18832696
申请日:2023-01-20
Applicant: XIAMEN UNIVERSITY , YANG SHENG TANG COMPANY, LTD.
Inventor: Wenxin LUO , Yue WANG , Yaxian MEI , Zhenghong AO , Yuanzhi CHEN , Jixian TANG , Yichao JIANG , Xiaoqing CHEN , Tianying ZHANG , Quan YUAN , Ningshao XIA
IPC: C07K16/08 , A61K39/00 , A61P31/20 , C07K14/005 , C12N15/85
Abstract: The present invention relates to the field of molecular virology and immunology, in particular to the field of hepatitis B virus (HBV) infection treatment. In particular, the present invention relates to an epitope peptide (or a variant thereof) capable of treating a hepatitis B virus infection, a recombinant protein comprising the epitope peptide (or a variant thereof) and a carrier protein, and an antibody (e.g. a nanobody) for the epitope peptide. The epitope peptide and antibody of the present invention can be used to prevent and/or treat HBV infection or a disease related to HBV infection (e.g. hepatitis B), for reducing the serum level of HBV DNA and/or HBsAg in a subject (e.g. a human), or for activating a subject (e.g. a chronic HBV infected person or a chronic hepatitis B patient) against HBV humoral immune response.
-
公开(公告)号:US20220251173A1
公开(公告)日:2022-08-11
申请号:US17613392
申请日:2020-05-22
Applicant: XIAMEN UNIVERSITY , YANG SHENG TANG COMPANY, LTD.
Inventor: Wenxin LUO , Yichao JIANG , Chao YU , Xiaoqing CHEN , Jixian TANG , Quan YUAN , Tianying ZHANG , Ningshao XIA
Abstract: Antibodies (especially humanized antibodies) against the hepatitis B surface antigen (HBsAg), a nucleic acid molecule encoding same, a method for preparing same, and a pharmaceutical composition containing same. The anti-HBsAg antibodies have a higher binding affinity to HBsAg at a neutral pH than at an acidic pH, thereby significantly enhancing virus clearance efficiency and prolonging virus inhibition time. The antibodies and pharmaceutical composition may be used to prevent and/or treat HBV infections or diseases related to HBV infection (such as hepatitis B) for use in neutralizing the virulence of HBV in the body of a subject (such as a human) to reduce a serum level of HBV DNA and/or HBsAg in the body of the subject, or to activate a humoral immune response of a subject (such as a person infected with chronic HBV or a patient who has chronic hepatitis B) against HBV.
-
公开(公告)号:US20210154249A1
公开(公告)日:2021-05-27
申请号:US17047783
申请日:2019-04-15
Applicant: Xiamen University , Yang Sheng Tang Company, Ltd.
Inventor: Tong CHENG , Wei WANG , Xiangzhong YE , Wenkun FU , Dequan PAN , Jun ZHANG , Ningshao XIA
Abstract: Provided are Coxsackie virus CVB1 or a modified form thereof, or a genomic sequence or cDNA sequence comprising CVB1 or the modified form thereof, or a nucleic acid molecule of a complement sequence of the genomic sequence or cDNA sequence, the use of same for treating tumors in subjects including humans, and the use of same in the preparation of a pharmaceutical composition for treating tumors in subjects including humans. Also provided is a method for treating tumors, comprising administering CVB1 or the modified form thereof, or the genomic sequence or cDNA sequence comprising CVB1 or the modified form thereof, or the nucleic acid molecule of the complement sequence of the genomic sequence or cDNA sequence to a subject in need thereof.
-
公开(公告)号:US20200268869A1
公开(公告)日:2020-08-27
申请号:US15781035
申请日:2016-12-02
Applicant: Xiamen University , Xiamen Innovax Biotech Co., Ltd.
Inventor: Shaowei LI , Zhihai LI , Shuo SONG , Maozhou HE , Ying GU , Ningshao XIA
IPC: A61K39/12 , C07K14/005 , C12N7/00 , A61P31/20 , C12N15/70
Abstract: Provided are a mutated HPV58 L1 protein or a variant thereof, a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein or a variant thereof and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types, and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. The invention further relates to the use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.
-
-
-
-
-
-
-
-
-